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he Skinny on Fatty
cid-Binding Protein*
ames A. de Lemos, MD, FACC,†
ichelle O’Donoghue, MD‡
allas, Texas; and Boston, Massachusetts
iomarkers have come to play an increasingly important
ole in the evaluation and management of patients with
uspected acute coronary syndromes (ACS). To date, car-
iac troponins T and I remain the best established biomar-
ers in ACS for both diagnosis and risk assessment. In
ddition to providing high sensitivity and specificity for
etecting myocardial necrosis, troponins provide assessment
f the risk of adverse outcomes in patients with ACS and
elp to identify patients who benefit most from particular
reatment strategies, including glycoprotein IIb/IIIa inhib-
tors, low molecular-weight heparins, and routine coronary
ngiography (1).
See page 2061
Advances in methodologies for protein identification and
greater understanding of the inflammatory pathophysiol-
gy of atherothrombosis have contributed to a proliferation
f candidate biomarkers in ACS over the past several years.
any of these novel markers reflect pathways that are
istinct from myocardial necrosis, because it is largely
elieved that high-quality troponin assays allow little room
or other markers of necrosis. Recent guidelines, in fact,
ecommend that troponins are the only necrosis markers
hat should be measured routinely for diagnosis and risk
tratification in ACS (1).
However, despite a robust evidence base supporting their
outine measurement in ACS, troponins have several im-
ortant limitations. In particular, because of troponins’
elative large size and location bound within the contractile
pparatus of the cardiomyocyte, troponin release is typically
elayed for several hours after the onset of ischemic injury.
hus, blood must be sampled at least 6 h after the onset of
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ics, Inverness, and Tethys and grant support from Biosite and Roche Diagnostics.schemic discomfort in order to achieve adequate sensitivity.
s such, for a large number of patients without classic
ymptomatology or electrocardiographic changes, signifi-
ant irreversible myocardial injury might occur before a
efinitive therapeutic plan is implemented. In addition,
roponin levels might remain elevated for 7 to 14 days after
he initial ischemic insult, thereby limiting sensitivity for
etecting recurrent myocardial injury. Importantly, because
urrent troponin assays are unable to detect ischemia in the
bsence of necrosis, troponins are unable to identify patients
ith unstable angina who are at increased risk of adverse
utcomes and who might benefit from specific treatment
trategies. Finally, it is increasingly recognized that, among
ospitalized patients, a substantial proportion of elevated
roponin levels are caused by conditions other than ACS (2).
roponins, although specific for myocardial necrosis, are by
o means specific for acute plaque rupture leading to
schemic injury.
In the current issue of the Journal, Kilcullen et al. (3)
eport on the prognostic utility of heart-type fatty acid-
inding protein (H-FABP) in patients with ACS. Heart-
ype fatty acid-binding protein is a biomarker of myocardial
ecrosis and injury that offers several theoretical advantages
ver troponin. Heart-type fatty acid-binding protein is
maller in size (14 to 15 kDa) than troponin I or T (21 to
7 kDa) and is concentrated in the cytoplasm of cardiomy-
cytes. Owing to its small size, H-FABP is released quickly
nto the circulation when membrane integrity is compro-
ised in response to myocardial injury. Levels of H-FABP
re detectable as early as 2 to 3 h and typically return to
aseline levels within 12 to 24 h of the initial insult (4,5).
onsistent with these findings, a growing number of studies
ave shown that H-FABP is a sensitive marker for the
iagnosis of myocardial infarction (MI) (4,6–8) and might
e more sensitive than older-generation troponin assays
hen measured in the early hours after symptom onset
8,9). Moreover, because of its rapid release kinetics,
-FABP might be useful for the detection of reperfusion
fter ST-segment elevation MI (10). These properties
heoretically make H-FABP an attractive marker both for
he detection of myocardial ischemia in the absence of
ecrosis and possibly for the early detection of recurrent
yocardial injury. To date, however, there is no definitive
vidence to show that ischemic injury below the threshold
or necrosis can lead to H-FABP release.
We recently reported that elevated levels of H-FABP
easured in the first few days after an ACS event were
ssociated with an increased risk of death, heart failure, and
arly recurrent ischemic events (11). Moreover, H-FABP
eemed to provide incremental information for risk stratifi-
ation that was independent of established risk factors and
iomarkers, including troponin I, B-type natriuretic pep-
ide, and myoglobin. Because H-FABP is released and
leared rapidly from the circulation, we hypothesized that
levation in serum H-FABP at this later time point (41 
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November 20, 2007:2068–70 Editorial Comment0 h) might help to identify patients with either ongoing or
ecurrent myocardial injury who are at particular risk of
dverse outcomes (11). However an important limitation to
ur report was the use of an older generation troponin assay,
hich precluded definitive evaluation of the incremental
tility of H-FABP beyond that which is provided by newer
igh-sensitivity troponin assays (12).
In the current study, Kilcullen et al. (3) evaluated the
rognostic utility of H-FABP in a registry of 1,448 patients
ith ACS from West Yorkshire, United Kingdom. Heart-
ype fatty acid-binding protein was powerfully and indepen-
ently associated with the risk of death when measured
ithin 12 to 24 h of symptom onset after ACS. Moreover,
-FABP identified subjects at increased risk of death even
hen troponin levels were normal. This study provides
mportant confirmatory information to substantiate the
rognostic utility of this emerging marker and addresses the
ost important limitations of our prior study. In particular,
he current analysis employed the use of higher-sensitivity
ssays for the assessment of both troponin (Accu TnI, Beck-
an Coulter, Fullerton, California) and H-FABP (Dainippon
harmaceutical, Osaka, Japan). In the presence of a negative
roponin I (0.06 ng/ml), an elevation in H-FABP (5.8
g/l) was associated with a significant increase in the risk of
eath after adjusting for variables in the GRACE (Global
egistry of Acute Coronary Events) prediction model and
or levels of C-reactive protein.
Several limitations to the current study merit consider-
tion. Few subjects with unstable angina were included, and
herefore it will be important to further delineate the role of
-FABP in a well-defined population of patients with
nstable angina in the future. In addition, the authors did
ot measure myoglobin in the present study. Although
yoglobin has a molecular weight and kinetic profile similar
o H-FABP, a much higher proportion of H-FABP is
oncentrated in myocardial tissue (vs. skeletal muscle) rela-
ive to myoglobin. Thus, H-FABP might offer improved
pecificity and sensitivity over myoglobin, owing to its
elative predominance in myocardial tissue and lower nor-
al reference range (7,8,13). Nevertheless, elevated levels of
yoglobin have also been associated with an increased risk
f death and heart failure after ACS (14), and additional
irect comparisons are needed to fully establish the superi-
rity of H-FABP over myoglobin for risk stratification.
These are “early days” in the lifespan of H-FABP, and
any important clinical, logistical, and scientific questions
emain to be answered. Because the present study measured
-FABP 12 to 24 h from symptom onset, the relative
iagnostic and prognostic value of the marker in the earliest
ours from symptom onset (when it should be most useful)
emains unclear. Earlier reports suggest that H-FABP is
ndeed useful for risk stratification when measured 6 h
rom symptom onset (15,16). Because only mortality data
ere collected in the current analysis, future studies are
eeded to determine whether H-FABP is useful for pre-
icting the risk of heart failure or early recurrent myocardialnjury. Moreover, it remains unknown whether H-FABP
ight help to guide selection of specific treatment strategies
n ACS.
Perhaps the most intriguing question that remains is why
-FABP might provide prognostic information for death
nd heart failure that is independent of and superior to
roponin. The answer to this question will teach us as much
r more about troponin as it does about H-FABP. It is of
nterest that the association of H-FABP (as well as myo-
lobin and creatine kinase-myocardial band) with infarct
ize seems to follow a straightforward single compartmental
odel, whereas the association between troponin and in-
arct size is considerably more complex. Although it is
empting to speculate that H-FABP elevation might iden-
ify ischemic injury below the threshold of detection with
roponin, mortality was considerably higher among patients
n this subgroup in the present study than one would expect
or patients with ACS who have normal troponin levels.
uture studies correlating H-FABP levels with necropsy find-
ngs among patients with normal troponin levels would be
articularly helpful for characterizing the mechanistic links
etween H-FABP elevation and mortality. Alternatively,
elayed-enhancement magnetic resonance imaging studies
ight allow delineation of differences in the relationships
etween various biomarkers of necrosis and myocardial injury.
t present, it seems the most plausible hypothesis is that
levated levels of H-FABP at later time points might identify
atients with either ongoing or recurrent myocardial injury
ho are at increased risk of death.
Although much further investigation will be required
efore the clinical use of H-FABP can be considered, the
urrent study provides early confirmatory evidence to sug-
est that this biomarker might help to identify high-risk
atients who are troponin negative. Although troponins
emain the benchmark for ACS biomarkers, they have
mportant limitations, and investigators should continue to
valuate other biomarkers in the necrosis class, provided
heir incremental utility relative to state-of-the-art troponin
ssays can be definitively established.
eprint requests and correspondence: Dr. James A. de Lemos,
niversity of Texas Southwestern Medical Center, 5909 Harry
ines Boulevard, HA 9.133, Dallas, Texas 75390. E-mail: James.
eLemos@UTSouthwestern.edu.
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